Pfizer
Dave M. Denton is the Chief Financial Officer and Executive Vice President for Pfizer. Dave is a member of Pfizer’s Executive Leadership Team (ELT), providing strategic global financial leadership. Dave leads the corporate finance functions including audit, treasury, tax, insurance, operations planning and analysis (OP&A), corporate controllership, and business finance and analytics.
Dave has more than 25 years of finance and operational expertise, including more than 20 years in the healthcare sector. As a result, he brings to Pfizer a unique perspective on the role of payers, the needs of patients, and the rapidly evolving healthcare landscape.
Prior to joining Pfizer, Dave was the CFO and Executive Vice President of Lowe’s Companies Inc. He joined Lowes in 2018 and was responsible for all of Lowe’s financial functions and processes. This includes corporate finance and treasury, strategy, real estate, accounting, tax, internal audit and risk management.
Before joining Lowe's, he served as executive vice president and CFO of CVS Health, where he was responsible for all aspects of financial planning and management. Dave played a key role in CVS’s transformational journey from a retail pharmacy to the health solutions company it is today and led the full integration of Caremark into CVS. In December 2017, he played a pivotal role in one of the largest healthcare transactions in history when CVS acquired Aetna - structuring and negotiating the terms and financing for the transaction.
Before being named the CFO of CVS Health, Dave held several leadership roles at CVS, including Senior Vice President and Controller/Chief Accounting Officer. Prior to CVS, Dave was with the management consulting firm of Deloitte Touche Tohmatsu.
Dave earned a bachelor's degree in business administration from Kansas State University and an MBA from the Babcock Graduate School of Management at Wake Forest University. He serves on the board of Tapestry, Inc.
Pfizer
606 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.